Spezifische Plasmínogenaktivatorinhíbitoren

• Literatur

• 1 Danø K, Andreasen P.A, Grøndahl-Hansen J, Kristensen P, Nielsen L.S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
• 2 Thorsen S, Philips M. Plasminogen activator inhibitors. In: Castellino et al. (eds) Fundamental and Clinical Fibrinolysis. Amsterdam: Elsevier Science; 1987. chapter 7 (83): 98.
• 3 Sprenger E.D, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
• 4 Åstedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1987; 1: 203-8.
• 5 Stump D.C, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. J Biol Chem 1986; 261: 12759-66.
• 6 Baker J.B, Low D.A, Simmer R.L, Cunningham D.D. Proteasenexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980; 21: 37-45.
• 7 Scott R.W, Bergman B.L, Bajpai A, Hersh R.T, Rodriguez H, Jones B.N, Barreda C, Watts S, Baker J.B. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985; 260: 7029-34.
• 8 Brakman P, Astrup T. Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis. Scand J Clin Lab Invest 1963; 15: 603-9.
• 9 Thorsen S, Brakman P, Astrup T. Influence of platelets on fibrinolysis. A critical review. Hematol Rev 1972; 3: 123-79.
• 10 Kawano T, Morimoto K, Uemura Y. Urokinase inhibitor in human placenta. Nature 1968; 217: 253-4.
• 11 Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 1970; 67: 333-42.
• 12 Kawano T, Uemura Y. Inhibition of tissue activator by urokinase inhibitor. Thromb Diathes Haemorrh 1971; 25: 129-33.
• 13 Bernik M.B, Kwaan H.C. Inhibitors of fibrinolysis in human tissues in culture. Am J Physiol 1971; 221: 916-21.
• 14 Åstedt B, Pandolfi M, Nilsson I.M. Inhibitory effect of placenta on plasminogen activation in human organ culture. Proc Soc Exp Biol Med 1972; 139: 1421-4.
• 15 Holmberg L, Lecander I, Persson B, Åstedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-37.
• 16 Levin E.G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci 1983; 80: 6804-8.
• 17 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-36.
• 18 Erickson L.A, Ginsberg M.H, Loskutoff D.J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
• 19 Kruithof E.K.O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
• 20 van Mourik J.A, Lawrence D.A, Loskutoff D.J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-21.
• 21 Philips M, Juul A-G, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Bio-chim Biophys Acta 1984; 802: 99-110.
• 22 Sprengers E.D, Verheijen J.H, van Hins-bergh V.W.M, Emeis J.J. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163-70.
• 23 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802: 111-8.
• 24 Verheijen J.H, Chang G.T.G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-5.
• 25 Wiman B, Chmielewska J, Rånby M. Inac-tivation of tissue plasminogen activator in plasma; demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-7.
• 26 Sprengers E.D, Princen H.M.G, Kooistra T, van Hinsbergh V.W.M. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-8.
• 27 Coleman P.L, Patel P.D, Cwikel B.J, Rafferty U.M, Sznycer-Laszuk R, Gelehrter T.D. Characterization of the dexame-thasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 1986; 261: 4352-7.
• 28 Loskutoff D.J, Roegner K, Erickson L.A, Schleef R.R, Huttenlocher A, Coleman P.L, Gelehrter T.D. The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells. Thromb Haemost 1986; 55: 8-11.
• 29 Ny T, Bjersing L, Hsueh A.J.W, Loskutoff D.J. Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology 1985; 116: 1666-8.
• 30 Nielsen L.S, Andreasen P.A, Grøndahl-Hansen J, Huang J-Y, Kristensen P, Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells -inhibitor neutralization and one-step affinity purification. Thromb Haemost 1986; 55: 206-12.
• 31 Philips M, Juul A.G, Thorsen S, Selmer J, Thim L. Purification and characterization of reactive and non-reactive plasminogen activator inhibitor-1 (PAT-1) from human placenta. XIth International Congress on Thrombosis and Haemostasis. Thromb Haemost 1987; 58 abstr 7
• 32 Lecander I, Roblin R, Åstedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br J Haematol 1984; 57: 407-12.
• 33 Åstedt B, Lecander I, Brodin T, Lundblad A, Low K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 1985; 53: 122-5.
• 34 Wun T-C, Reich E. An inhibitor of plasminogen activation from human placenta. J Biol Chem 1987; 262: 3646-53.
• 35 Lecander I, Åstedt B. Specific plasminogen activator inhibitor of placental type PAI-2 occurring in amniotic fluid and cord blood. J Lab Clin Med 1987; 110: 602-5.
• 36 Åstedt B, Hägerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 1986; 56: 63-5.
• 37 Golder J.P, Stephens R.W. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem 1983; 136: 517-22.
• 38 Chapman Jr H.A, Stone O.L. Characterization of a macrophage-derived plasminogen activator inhibitor. Biochem J 1985; 230: 109-16.
• 39 Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-397). Int J Cancer 1976; 17: 565-77.
• 40 Vassalli J-D, Dayer J-M, Wohlwend A, Belin D. Concomitant secretion of prouro-kinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-68.
• 41 Kruithof E.K.O, Vassalli J-D, Schleuning W-D, Mattaliano R.J, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986; 261: 11207-13.
• 42 Kruithof E.K.O, Cajot J-F, Bachmann F. Comparative studies on PA-inhibitors of different sources. 8th International Congress on Fibrinolysis 1986, Abstr 31.
• 43 Lecander I, Martinsson G, Nielsen L.S, Andreasen P.A, Danø K, Åstedt B. Plasminogen activator inhibitors of type 1 (PAI-1) and type 2 (PAI-2) are present in ascitic fluid from patients with ovarian carcinoma. Xlth International Congress on Thrombosis and Haemostasis 1987, Abstr 1663.
• 44 Stief T.W, Radtke K-P, Heimburger N. Evidence for identity of PCI and plasminogen activator inhibitor 3. Inhibition of urokinase by protein C-inhibitor (PCI). Hoppe-Seylers Z Biol Chem 1987; 368: 1427-33.
• 45 Ny T, Sawdey M, Lawrence D, Millan J.L, Loskutoff D.J. Cloning and sequence of a cDNA coding for the human ß-migration endothelial cell-type plasminogen activator inhibitor. Proc Natl Acad Sci 1986; 83: 6776-81.
• 46 Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij C.L, van Zonne-veld A-J, van Mourik J.A. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2539-44.
• 47 Hekman C.M, Loskutoff D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by dénaturants. J Biol Chem 1985; 260: 11581-7.
• 48 Andreasen P.A, Nielsen L.S, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986; 261: 7644-51.
• 49 Sprengers E.D, Akkerman J.W.N, Jansen B.G. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325-9.
• 50 Levin E.G, Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood 1987; 70: 1090-8.
• 51 Ye R.D, Wun T-C, Sadler J.E. cDNA cloning and expression in escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987; 262: 3718-25.
• 52 Ny T, Hansson L, Åstedt B. Isolation of cDNA for type-2 plasminogen activator inhibitor. Xlth International Congress on Thrombosis and Haemostasis, 1987, Abstr 56.
• 53 Lecander I, Åstedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221-8.
• 54 Genton C, Kruithof E.K.O, Schleuning W-D. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol 1987; 104: 705-12.
• 55 Wholwend A, Belin D, Vassalli J-D. Plasminogen activator – specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987; 165: 320-39.
• 56 Philips M, Juul A-G, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110.
• 57 Erickson L.A, Hekman C.M, Loskutoff J.D. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci 1985; 82: 8710-4.
• 58 Wallen P, Ránby M, Bergsdorf N, Kok P. Purification and characterization of tissue plasminogen activator: on the occurrence of two different forms and their enzymatic properties. In: Davidson J.F, Nilssn I.M, Åstedt B. (eds) Progress in Fibrinolysis.
• 59 Åstedt B, Bladh B, Christensen U, Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripep-tide-p-nitroanilide substrates. Scand J Clin Lab Invest 1985; 45: 429-35.
• 60 Stenflo J. Structure and function of protein C. Semin Thromb Hemost 1984; 10: 109-21.
• 61 Marlar R.A, Kleiss A.J, Griffin J.H. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-72.
• 62 Suzuki K, Nishioka J, Hashimoto S. Protein C Inhibitor – Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-8.
• 63 Heeb M.J, Espana F, Geiger M, Collen D, Stump D.C, Griffin J.H. Immunological identity of Heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 1987; 262: 15813-6.
• 64 Ny T, Sawdey M, Lawrence D, Millan J.L, Loskutoff D.J. Cloning and sequence of a cDNA coding for the human ß-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
• 65 Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij C.L, van Zonne-veld A, van Mourik J. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2539-44.
• 66 Ginsburg D, Zehab R, Yang A.Y, Rafferty U.M, Andreasen P.A, Nielsen L, Danø K, Lebo R.V, Gelehrter T.D. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-80.
• 67 Andreasen P.A, Riccio A, Welinder K.G, Douglas R, Sartorio R, Nielsen L.S, Op-penheimer C, Danø K. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
• 68 Sawdey M, Ny T, Loskutoff D.J. Messenger RNA for plasminogen activator inhibitor. Thromb Res 1986; 41: 151-60.
• 69 Lawrence D.A, Loskutoff D.K. Inactiva-tion of plasminogen activator by oxidants. Biochemistry 1986; 25: 6353-5.
• 70 Ye R.D, Wun T-C, Sadler J.E. cDNA cloning and expression in escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987; 262: 3718-25.
• 71 Ny T, Hansson L, Åstedt B. Isolation of cDNA for type-2-plasminogen activator inhibitor. Xlth International Congress on Thrombosis and Haemostasis 1987, Abstr 56.
• 72 Kiso U, Kaudewitz H, Henschen A, Åstedt B, Kruithof E.K.O, Bachmann F. Determination of intermediates, products and cleavage site in the reaction between plasminogen activator inhibitor type-2 and urokinases. FEBS Lett 1988; 230: 51-6.
• 73 Kiso U, Kaudewitz H, Henschen A, Åstedt B. Proteinchemical determination of the structure of PAI-2 of human placenta: a comparison between the protein and DNA sequence data and analysis of N-terminus, cyst(e)ine residues and carbohydrate side chains. IXth International Congress on Fibrinolysis 1988; 2 Abstr 125
• 74 Ye R.D, Wun T-C, Sadler J.E. Mammalian protein secretion without signal peptide removal. J Biol Chem 1988; 263: 4869-75.
• 75 Speiser W, Bowry S, Anders E, Binder B.R, Müller-Berghaus G. Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-CAP) in plasma, platelets and endothelial cells. Thromb Res 1986; 44: 503-15.
• 76 Nilsson K, Rosen S, Friberger P. A new kit for the determination of tissue plasminogen activator and its inhibitor in blood. Fibrinolysis 1987; 1: 163-8.
• 77 Stief T.W, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle. Thromb Res 1988; 50: 559-75.
• 78 Kruithof E.K.O, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
• 79 Jørgensen M, Philips M, Thorsen S, Selmer J, Zeuthen J. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma. Thromb Haemost 1987; 58: 872-8.
• 80 Lecander I, Nilsson I.M, Åstedt B. Depression of plasminogen activator activity during pregnancy by the placental inhibitor PAI-2. Fibrinolysis (in press).
• 81 Urdén G, Chmielewska J, Carlsson T, Wiman B. Immunological relationship between plasminogen activator inhibitors from different sources. Thromb Haemost 1987; 57: 29-34.
• 82 Lund L.R, Riccio A, Andreasen P.A, Nielsen L.S, Kristensen P, Laiho M, Saksela O, Blasi F, Danø K. Transforming growth factor β is a strong and fast acting positive regulator of the level of type 1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987; 6: 1281-6.
• 83 Andreasen P.A, Pyke C, Riccio A, Kristensen P, Nielsen L.S, Lund L.R, Blasi F, Danø K. Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells. Mol Cell Biol 1987; 7: 3021-5.
• 84 Nielsen L.S, Lecander I, Andreasen P.H, Henschen A, Åstedt B, Danø K. Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies. Thromb Res 1987; 46: 411-23.
• 85 Aillaud M.F, Pignol F, Alessi M.C, Harle J.R, Escande M, Mongin M, Juahan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebr and Factor, Factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 1986; 55: 330-2.
• 86 Lecander I, Åstedt B. Occurrence of a specific plasminogen activator inhibitor of placental type, PAI-2, in men and nonpregnant women. Fibrinolysis (in press).
• 87 Juhan-Vague I, Moerman B, de Cock F, Aillaud M.F, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-30.
• 88 Kruithof E.K.O, Tran-Thang C, Bachmann F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost 1986; 55: 65-9.
• 89 Murano G, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-6.
• 90 Korninger C, Collen D. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemost 1981; 46: 662-5.
• 91 Rånby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 1982; 27: 175-83.
• 92 Waller K, Schleuning W-D, Reich E. Complex-formation and inhibition of urokinase by blood plasma proteins. Biochem J 1983; 215: 123-31.
• 93 Wiman B, Chmieleswska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-6.
• 94 Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 1984; 33: 49-53.
• 95 Fuchs H.E, Berger H, Pizzo S.V. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-44.
• 96 Isacson S, Nilsson I.M. Defective fibrinolysis in blood and vein walls in recurrent “idiopatie” venous thrombosis. Acta Chir Scand 1972; 138: 313-9.
• 97 Astrup T. Fibrinolysis: an overview. In: Davidson et al. (eds) Progr Chem Fibrinol Thromb. New York: Raven Press; 1978. 3: 1-57.
• 98 Nilsson I.M, Krook H, Sternby N.H, Söderberg E, Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor of the fibrinolytic system. Acta Med Scand 1961; 169: 323-37.
• 99 D’Angelo A, Kluft C, Verheijen J.H, Rijken D.C, Mozzi E, Mannucci A. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 1985; 15: 308-12.
• 100 Nilsson I.M, Ljungnér H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-6.
• 101 Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-70.
• 102 Pizzo S.V, Fuchs H.E, Doman K.A, Petruska D.B, Berger H. Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. Arch Int Med 1986; 146: 188-91.
• 103 Jørgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-80.
• 104 Sakata Y, Loskutoff D.J, Gladson C.L, Hekman C.M, Griffin J.H. Mechanism of protein C – dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 1218-23.
• 105 de Fouw N.J, van Hinsbergh V.W.M, de Jong Y.F, Haverkate F, Bertina R.M. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987; 57: 176-82.
• 106 Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haemat 1970; 7: 212.
• 107 Cwikel B.J, Barouski-Miller P.A, Coleman P.L, Gelehrter T.D. Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 1984; 259: 6847-51.
• 108 Åstedt B. Low fibrinolytic activity of veins during treatment with ethinyloestradiol. Acta Obstet Gynecol Scand 1971; 50: 279-83.
• 109 Verheijen J.H, Rijken D.C, Chang G.T.C, Preston F.E, Kluft C. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemost 1984; 51: 396-7.
• 110 Biezenski J.J, Moore H.C. Fibrinolysis in normal pregnancy. J Clin Path 1958; 11: 306.
• 111 Brakman P. The fibrinolytic system in human blood during pregnancy. Am J Obstet Gynecol 1966; 94: 14-20.
• 112 Nilsson I.M, Kullander S. Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand 1967; 46: 273-85.
• 113 Bonnar J, McNicol G.P, Douglas A.S. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3: 387-9.
• 114 Bonnar J, McNicol G.P, Douglas A.S. Coagulation and fibrinolytic mechanisms during and after childbirth. Br Med J 1970; 2: 200-3.
• 115 Åstedt B, Isacson S, Nilsson I.M, Pandolfi M. Fibrinolytic activity of veins during pregnancy. Acta Obstet Gynecol Scand 1970; 48: 171-3.
• 116 Astedt B. Demonstration of significance of placenta in depression of fibrinolytic activity during pregnancy. J Obst Gyn Br Commonw 1972; 79: 205-6.
• 117 Thorsen S. The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects. Scand J Clin Lab Invest 1973; 31: 51-9.
• 118 Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemost 1984; 52: 124-6.
• 119 Nilsson I.M, Feiding P, Lecander I, Lennér C, Astedt B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br J Haematol 1986; 62: 215-20.
• 120 Lecander I, Nilsson I.M, Astedt B. Depression of plasminogen activator activity during pregnancy by the placental inhibitor PAI-2. Fibrinolysis (in press).
• 121 Ikeuchi M. The study of local fibrinolysis in abortion. Acta Obstet Gynaecol Jpn 1985; 37: 1215-23.
• 122 Svanberg L, Åstedt B, Nilsson I.M. Abruptio placentae – treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 127-30.
• 123 Holmberg L, Kristoffersson A-C, Lecander I, Wallén P, Astedt B. Immunoradio-metric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase. Scand J Clin Lab Invest 1982; 42: 347-54.
• 124 Reich E. Activation of plasminogen: a widespread mechanism for generating localized extracellular proteolysis. In: Ruddon (ed) Biological Markers of Neoplasia: Basic and Applied Aspects. Amsterdam: Elsevier North Holland; 1978: 491-500.
• 125 Shinnar S, Molteni R.A, Gammon K, D’Souza B.J, Altman J, Freeman J.F. Intraventricular haemorrhage in the premature infant. N Engl J Med 1982; 306: 1464-8.
• 126 Rayburn F.W, Donn S.M, Kolin M.G, Schork A. Obstetric care and intraventricular hemorrhage in the low birth weight infant. Obstet Gynecol 1983; 62: 408-13.
• 127 Rånby M, Bergsdorf N, Pohl G, Wallén P. Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett 1982; 146: 289-92.
• 128 Peterson H.I. Fibrinolysis and antifibrino-lytic drugs in the growth and spread of tumours. Cancer Treat Rev 1977; 4: 213-7.
• 129 Astedt B, Tropé C. Effect of tranexamic acid on progress of experimental tumours and on DNA-synthesis. Experientia 1980; 36: 679-80.
• 130 Peterson H.I, Sundbeck A. Mechanisms behind experimental tumour growth inhibition by tranexamic acid. In: Davidsson J.F, Nilsson I.M, Åstedt B. (eds) Progress in Fibrinolysis. Edinburgh: Churchill Livingstone; 1981. V: 105-7.
• 131 Corasanti J.G, Hobika G.H, Markus G. Interference with dimethylhydrazine induction of colon tumors in mice by E-aminocaproic acid. Science 1982; 216: 1020-1.
• 132 Åstedt B, Glifberg I, Mattsson W, Tropé C. Arrest of growth of ovarian tumor by tranexamic acid. JAMA 1977; 237: 154-5.
• 133 Åstedt B. Adjuvant treatment of ovarian carcinoma with tranexamic acid. J Clin Pathol 1980; 33 (Suppl. 14) 74-6.
• 134 Åstedt B, Henriksson P, Nilsson I.M, Svanberg L. Regression of hemangioma -thrombocytopenia syndrome. Acta Obstet Gynecol Scand 1982; 62: 479-80.